STAT3 as a Target in H3K27M-mutant DMGs

“Children diagnosed with these tumors have [...] a median survival of approximately 12 months.” 

BUFFALO, NY- October 9, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on October 4, 2023, entitled, “STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma.”

Pediatric H3K27M-mutant diffuse midline gliomas (DMGs), including those formerly classified as diffuse intrinsic pontine gliomas (DIPG), are uniformly lethal central nervous system malignancies. Children diagnosed with these tumors have an extremely poor prognosis, with a median survival of approximately 12 months. The current standard of care for DMG includes possible biopsy for diagnostic confirmation and a 6-week course of palliative radiation. Despite enormous effort toward the development of novel therapeutics in DMG, chemotherapy remains ineffective in this disease. 

“Indeed, over 100 clinical trials for chemotherapeutics in DMG have failed to show therapeutic benefit [5].”

In their new editorial perspective, researchers Jacob B. Anderson, Samantha M. Bouchal, Liang Zhang, and David J. Daniels from the Mayo Clinic discussed the currently available literature and their recent study on the Signal Transducer and Activator of Transcription (STAT) as a biologically relevant therapeutic target in H3K27M-mutant DMGs. In their recently published manuscript, the lab performed a screen of drugs currently in clinical use or clinical trials for efficacy against a library of H3K27Mmutant and H3-wildtype patient-derived cell lines. The results of this drug screen identified the STAT3 signaling pathway as a novel target in DMG.

“Until recently, however, STAT3 was not a druggable target.” 

Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28516 

Correspondence to: David J. Daniels

Email: daniels.david@mayo.edu 

Keywords: H3K27M, DMG, DIPG, midline glioma, STAT3

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open-access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

X, formerly known as Twitter
Facebook
YouTube
Instagram
LinkedIn
Pinterest
LabTube
SoundCloud

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28516

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact media@impactjournals.com.

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)